Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | FADS1 | O60427 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | GLP1R | P43220 | 1/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2245636 | 0.85 | GBA1 (0.44) | GBA1EGFRAURKARPS6KB1FADS1 | |
| SCHEMBL27780844 | 0.84 | GBA1 (0.50) | GBA1EGFRAURKARPS6KB1FADS1 | |
| SCHEMBL1615945 | 0.76 | GBA1 (0.48) | GBA1EGFRAURKARPS6KB1FADS1 | |
| SCHEMBL1615946 | 0.76 | GBA1 (0.48) | GBA1EGFRAURKARPS6KB1FADS1 | |
| SCHEMBL2904940 | 0.76 | GBA1 (0.47) | GBA1EGFRAURKARPS6KB1FADS1 | |
| SCHEMBL2906202 | 0.76 | GBA1 (0.47) | GBA1EGFRAURKARPS6KB1FADS1 | |
| SCHEMBL2906027 | 0.75 | GBA1 (0.45) | GBA1EGFRAURKARPS6KB1FADS1 | |
| SCHEMBL2905249 | 0.74 | HTR6 (0.47) | — | |
| SCHEMBL2925982 | 0.73 | GBA1 (0.41) | GBA1EGFRAURKARPS6KB1FADS1 | |
| SCHEMBL2241839 | 0.73 | KDM1A (0.40) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994324-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-09 | — | — | US | claimed |
| US-20090227584-A1 | 2-AMINOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | claimed |
| US-7994324-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20090227584-A1 | 2-AMINOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227584-A1 | 2-AMINOQUINOLINE DERIVATIVES | HTR5A, HTR2C, HTR2B | GBA1 1247/4885EGFR 4445/4885AURKA 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.